References
- Levy BS. Modern management of uterine fibroids. Acta Obstet Gynecol Scand 2008;87:812–23
- Parker WH. Uterine myomas: management. Fertil Steril 2007;88:255–71
- Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:655–76
- Imai A, Takagi H, Matsunami K, Ichigo S. Sequential management with gonadotropin-releasing hormone agonist and dienogest of endometriosis-associated uterine myoma and adenomyosis. In: Chaudhury K, Chakravarty B, ed. Endometriosis – basic concepts and current research trends. Slovenia: InTech; 2012:483–90
- Olive DL. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 2004;3:83–9
- Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–903
- Sverrisdóttir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004;22:3694–9
- Imai A, Sugiyama M, Furui T, Tamaya T. Treatment of perimenopausal women with uterine myoma: successful use of a depot GnRH agonist leading to a natural menopause. J Obstet Gynaecol 2003;23:518–20
- Tanishima S, Morio Y. A review of minodronic acid hydrate for the treatment of osteoporosis. Clin Interv Aging 2013;8:185–9
- Ito M, Sone T, Fukunaga M. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab 2010;28:334–41
- Hagino H, Kishimoto H, Ohishi H, et al. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone 2014;59:44–52
- Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36–42
- Kapoor A, Gupta A, Desai N, Ahn H. Effect of zoledronic acid on bone mineral density in men with prostate cancer receiving gonadotropin-releasing hormone analog. Prostate Cancer 2011;2011:176164
- Israeli R, Rosenberg S, Saltzstein D, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007;5:271–7
- Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038–42